CRADA (cooperative research and development agreement)

A CRADA is the agreement under which a federal laboratory and one or more outside parties, usually companies and sometimes universities, carry out research together. It was created by the Federal Technology Transfer Act of 1986 and is governed by 15 U.S.C. 3710a. The laboratory contributes personnel, facilities, equipment, and intellectual property. The partner contributes the same, plus money if it chooses. The one thing the statute forbids is the laboratory paying the partner.

How it works in a university-industry collaboration

A CRADA matters to university-industry work in two ways. A university can be the partner, when a lab's capability is what a project needs. More often, a company already working with a university adds a national laboratory as a third party, and the CRADA becomes the agreement everyone has to wait for.

The statute gives the laboratory room that a university's policies usually don't. The lab may grant the partner a license, or assign title outright, to inventions its own employees make under the agreement, and the partner keeps title to what its employees invent, subject to a government-use license. Information the partner brings in, and results the parties agree to protect, can be withheld from Freedom of Information Act disclosure for up to five years. What slows the negotiation is the manufacturing clause. The statute directs agencies to prefer partners that agree products embodying the inventions will be "manufactured substantially in the United States," and DOE applies that to its labs through a determination of exceptional circumstances. A company whose manufacturing is elsewhere needs a waiver, and DOE's own guidance says waivers "are heavily fact dependent and are rarely granted in full."

Published timelines are scattered and tell two stories. Labs without a waiver in play can be quick: NOAA quotes one to two months, the National Cancer Institute's technology transfer center targets six months or less, DOE's 2012 technology transfer plan set a 60-day target after one lab cut its cycle from 150 days to 45, and Sandia reported 78% of its CRADAs executed within 30 days in fiscal 2024. The averages are longer: the GAO measured 7.5 months at DOE's contractor-operated labs in 1994, and EPA's FY2023 report shows its own agreements averaging four to thirteen months over five years. Add two to three months when the partner is foreign-owned, and up to six when a USTR review applies. No agency publishes a clock for manufacturing waivers. Plan for the agreement, not the project, to be the critical path.

Translation Box: CRADA

On the laboratory side: a statutory instrument with its own approval chain, its own IP rules, and a mission test (does the work serve the lab's program?). The lab's technology transfer office runs it, and the lab's attorney signs it.

On the industry side: access to equipment and expertise that exist nowhere else, bought with time rather than money. The manufacturing clause is the term to raise in the first meeting, not the last, because it decides whether the agreement takes two months or one year or more.

What Helikon does with it

A Helikon project records the agreement type and the signed agreement with its dates, so a project that depends on a CRADA shows the agreement's status next to the milestones that wait on it. Partner search can find the university capability a company needs alongside a federal laboratory one, which is often the faster route.